WO2007150074A3 - Compositions comprising nanoparticulate naproxen and controlled release hydrocodone - Google Patents
Compositions comprising nanoparticulate naproxen and controlled release hydrocodone Download PDFInfo
- Publication number
- WO2007150074A3 WO2007150074A3 PCT/US2007/072052 US2007072052W WO2007150074A3 WO 2007150074 A3 WO2007150074 A3 WO 2007150074A3 US 2007072052 W US2007072052 W US 2007072052W WO 2007150074 A3 WO2007150074 A3 WO 2007150074A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrocodone
- compositions
- composition
- component
- controlled release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07799011A EP2032137A2 (en) | 2006-06-23 | 2007-06-25 | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
BRPI0713447-9A BRPI0713447A2 (en) | 2006-06-23 | 2007-06-25 | solid oral dosage form composition, and, method for treating pain |
MX2008016223A MX2008016223A (en) | 2006-06-23 | 2007-06-25 | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone. |
CA002660649A CA2660649A1 (en) | 2006-06-23 | 2007-06-25 | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
JP2009516756A JP2009541359A (en) | 2006-06-23 | 2007-06-25 | Composition comprising nanoparticulate naproxen and controlled release hydrocodone |
AU2007260821A AU2007260821B2 (en) | 2006-06-23 | 2007-06-25 | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
IL196065A IL196065A0 (en) | 2006-06-23 | 2008-12-18 | Compositions comrising nanoparticulate naproxen and controlled release hydrocodone |
NO20090158A NO20090158L (en) | 2006-06-23 | 2009-01-12 | Composition comprising naproxen nanoparticles and controlled release hydrocarbon |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81588506P | 2006-06-23 | 2006-06-23 | |
US60/815,885 | 2006-06-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007150074A2 WO2007150074A2 (en) | 2007-12-27 |
WO2007150074A3 true WO2007150074A3 (en) | 2008-04-10 |
Family
ID=38834446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/072052 WO2007150074A2 (en) | 2006-06-23 | 2007-06-25 | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP2032137A2 (en) |
JP (1) | JP2009541359A (en) |
KR (1) | KR20090024284A (en) |
CN (1) | CN101484170A (en) |
AU (1) | AU2007260821B2 (en) |
BR (1) | BRPI0713447A2 (en) |
CA (1) | CA2660649A1 (en) |
IL (1) | IL196065A0 (en) |
MX (1) | MX2008016223A (en) |
NO (1) | NO20090158L (en) |
WO (1) | WO2007150074A2 (en) |
ZA (1) | ZA200810221B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
US20040234602A1 (en) | 2001-09-21 | 2004-11-25 | Gina Fischer | Polymer release system |
ES2360102T3 (en) | 2003-03-26 | 2011-05-31 | Egalet A/S | SYSTEM FOR CONTROLLED RELEASE OF MORPHINE. |
AU2008258596B2 (en) | 2007-06-04 | 2013-02-14 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
NZ594207A (en) | 2009-02-06 | 2013-03-28 | Egalet Ltd | Immediate release composition resistant to abuse by intake of alcohol |
EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
ES2643291T3 (en) | 2010-12-22 | 2017-11-22 | Purdue Pharma L.P. | Controlled release dosage forms with inviolable closure coated |
CA2822769C (en) | 2010-12-23 | 2016-10-04 | Purdue Pharma L.P. | Tamper resistant solid oral dosage forms |
KR101794032B1 (en) | 2011-09-21 | 2017-11-07 | (주)바이오시네틱스 | Method for preparing nanoparticles |
EP2877161A1 (en) | 2012-07-06 | 2015-06-03 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
KR101840526B1 (en) | 2013-02-05 | 2018-03-20 | 퍼듀 퍼머 엘피 | Tamper resistant pharmaceutical formulations |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
CN112500694B (en) * | 2020-12-04 | 2022-03-29 | 东莞威赢高尔夫用品有限公司 | Electronic equipment veneer material and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6165506A (en) * | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
US20030129237A1 (en) * | 1998-11-02 | 2003-07-10 | Devane John G. | Multiparticulate modified release composition |
US20050031691A1 (en) * | 2002-09-11 | 2005-02-10 | Elan Pharma International Ltd. | Gel stabilized nanoparticulate active agent compositions |
-
2007
- 2007-06-25 WO PCT/US2007/072052 patent/WO2007150074A2/en active Application Filing
- 2007-06-25 CA CA002660649A patent/CA2660649A1/en not_active Abandoned
- 2007-06-25 AU AU2007260821A patent/AU2007260821B2/en not_active Expired - Fee Related
- 2007-06-25 EP EP07799011A patent/EP2032137A2/en not_active Withdrawn
- 2007-06-25 CN CNA2007800236169A patent/CN101484170A/en active Pending
- 2007-06-25 MX MX2008016223A patent/MX2008016223A/en not_active Application Discontinuation
- 2007-06-25 BR BRPI0713447-9A patent/BRPI0713447A2/en not_active IP Right Cessation
- 2007-06-25 JP JP2009516756A patent/JP2009541359A/en active Pending
- 2007-06-25 KR KR1020097001439A patent/KR20090024284A/en not_active Application Discontinuation
-
2008
- 2008-12-02 ZA ZA200810221A patent/ZA200810221B/en unknown
- 2008-12-18 IL IL196065A patent/IL196065A0/en unknown
-
2009
- 2009-01-12 NO NO20090158A patent/NO20090158L/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6165506A (en) * | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
US20030129237A1 (en) * | 1998-11-02 | 2003-07-10 | Devane John G. | Multiparticulate modified release composition |
US20050031691A1 (en) * | 2002-09-11 | 2005-02-10 | Elan Pharma International Ltd. | Gel stabilized nanoparticulate active agent compositions |
Also Published As
Publication number | Publication date |
---|---|
KR20090024284A (en) | 2009-03-06 |
NO20090158L (en) | 2009-03-20 |
ZA200810221B (en) | 2009-11-25 |
BRPI0713447A2 (en) | 2012-03-13 |
JP2009541359A (en) | 2009-11-26 |
MX2008016223A (en) | 2009-01-19 |
EP2032137A2 (en) | 2009-03-11 |
WO2007150074A2 (en) | 2007-12-27 |
CA2660649A1 (en) | 2007-12-27 |
IL196065A0 (en) | 2009-09-01 |
CN101484170A (en) | 2009-07-15 |
AU2007260821A1 (en) | 2007-12-27 |
AU2007260821B2 (en) | 2012-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007150075A3 (en) | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone | |
WO2007150074A3 (en) | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone | |
WO2006102610A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
WO2007109192A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
WO2006131591A3 (en) | An entacapone-containing oral dosage form | |
WO2010003127A3 (en) | Antagonists of prostaglandin d2 receptors | |
WO2008033351A3 (en) | Multimodal abuse resistant and extended release formulations | |
WO2007109160A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
IL195488A (en) | Compounds, pharmaceutical compositions comprising the same and uses thereof | |
IL196426A (en) | Microparticles based on an amphiphilic copolymer, processes for the preparation thereof and pharmaceutical compositions containing the same | |
WO2009145989A3 (en) | Aminoalkylphenyl antagonists of prostaglandin d2 receptors | |
EP2045251A4 (en) | Compound that can inhibit ubc13-uev interactions, pharmaceutical compositions and therapeutic uses | |
WO2006099514A3 (en) | Drug delivery compositions and related methods | |
IL192967A0 (en) | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof | |
WO2007019439A3 (en) | Block copolymer compositions and uses thereof | |
EP1986702A4 (en) | Hyperpolarization methods, systems and compositions | |
LT2029480T (en) | Biologicallly active nanoparticles of a carbonate-substituted hydroxyapatite, process for their preparation and compositions incorporating the same | |
WO2007109182A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
WO2007117556A3 (en) | Pharmaceutical compositions and uses thereof | |
WO2007109201A3 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
WO2007002823A3 (en) | Formulations of conjugated estrogens and bazedoxifene | |
WO2009087634A3 (en) | Methods and compositions for oral administration of insulin | |
WO2010066749A3 (en) | Ulipristal acetate tablets | |
WO2007028022A3 (en) | Novel compounds as p2x7 modulators and uses thereof | |
WO2009039157A3 (en) | Orlistat pharmaceutical formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780023616.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07799011 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007260821 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2660649 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007799011 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2008/016223 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 196065 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009516756 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007260821 Country of ref document: AU Date of ref document: 20070625 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097001439 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0713447 Country of ref document: BR Kind code of ref document: A2 Effective date: 20081222 |